ECSP088613A - Moléculas de anticuerpo que tienen especificidad para la il-6 humana - Google Patents

Moléculas de anticuerpo que tienen especificidad para la il-6 humana

Info

Publication number
ECSP088613A
ECSP088613A EC2008008613A ECSP088613A ECSP088613A EC SP088613 A ECSP088613 A EC SP088613A EC 2008008613 A EC2008008613 A EC 2008008613A EC SP088613 A ECSP088613 A EC SP088613A EC SP088613 A ECSP088613 A EC SP088613A
Authority
EC
Ecuador
Prior art keywords
antibody molecules
specificity
human
producing
methods
Prior art date
Application number
EC2008008613A
Other languages
English (en)
Inventor
Andrew George Popplewell
Richard Evan Gelinas
Mitra Choudhury Singhal
Yi Zhang
Ralph Adams
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37714544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088613(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of ECSP088613A publication Critical patent/ECSP088613A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se relaciona con las moléculas de anticuerpo que tienen especificidad para determinantes antigénicos de la IL-6, los usos terapéuticos de las moléculas de anticuerpo y los métodos para producir dichas moléculas de anticuerpo.
EC2008008613A 2005-12-09 2008-07-07 Moléculas de anticuerpo que tienen especificidad para la il-6 humana ECSP088613A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74892605P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
ECSP088613A true ECSP088613A (es) 2008-08-29

Family

ID=37714544

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008613A ECSP088613A (es) 2005-12-09 2008-07-07 Moléculas de anticuerpo que tienen especificidad para la il-6 humana

Country Status (27)

Country Link
US (5) US8075889B2 (es)
EP (3) EP2314626A1 (es)
JP (1) JP5183484B2 (es)
KR (2) KR101413451B1 (es)
CN (1) CN101356194B (es)
AR (1) AR057224A1 (es)
AU (1) AU2006323490B2 (es)
BR (1) BRPI0619595B8 (es)
CA (1) CA2632628C (es)
DK (1) DK1960430T3 (es)
EA (1) EA018044B1 (es)
EC (1) ECSP088613A (es)
ES (1) ES2525325T3 (es)
HR (1) HRP20141214T1 (es)
IL (2) IL191600A (es)
MY (1) MY147217A (es)
NO (1) NO344847B1 (es)
NZ (1) NZ569234A (es)
PE (1) PE20070998A1 (es)
PL (1) PL1960430T3 (es)
PT (1) PT1960430E (es)
RS (1) RS53708B1 (es)
SI (1) SI1960430T1 (es)
TW (1) TWI390035B (es)
UA (1) UA96141C2 (es)
WO (1) WO2007066082A1 (es)
ZA (1) ZA200804594B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
CA2632628C (en) 2005-12-09 2016-01-19 Ucb Pharma S.A. Antibody molecules having specificity for human il-6
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
CA2693310C (en) * 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
JP2011520898A (ja) 2008-05-13 2011-07-21 ノビミューン エスアー 抗ｉｌ−６／ｉｌ−６ｒ抗体およびそれらの使用方法
KR20110094307A (ko) * 2008-11-13 2011-08-23 펨타 파마슈티컬스, 인크. 인간화된 항-ｉｌ-6 항체
KR20110091780A (ko) 2008-11-25 2011-08-12 앨더 바이오파마슈티컬즈, 인코포레이티드 악액질, 쇠약, 피로 및／또는 발열을 예방하거나 치료하는 ｉｌ­６의 길항제
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
RU2012110580A (ru) * 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Способы скрининга in vivo
CA2771702A1 (en) * 2009-08-21 2011-02-24 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and loxl2
BR112012019693A2 (pt) * 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
US8992908B2 (en) 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
US9289467B2 (en) * 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
WO2013086419A1 (en) * 2011-12-09 2013-06-13 California Institute Of Technology Polymer scaffolds and their use in the treatment of vision loss
WO2013175276A1 (en) * 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
WO2014066167A1 (en) * 2012-10-22 2014-05-01 Fountain Biopharma Inc. Antibodies to interleukin-6 and uses thereof
US20150239970A1 (en) * 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
US20190192692A1 (en) * 2016-05-05 2019-06-27 The Trustees Of The University Of Pennsylvania DNA Monoclonal Antibodies Targeting IL-6 and CD126
US20200306283A1 (en) 2016-06-22 2020-10-01 William Warren HARLESS Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neu1 sialidase inhibitor or a cytokine inhibitor after primary cancer treatment
CN106413047A (zh) * 2016-10-31 2017-02-15 北京小米移动软件有限公司 智能设备接入无线网络的方法和装置
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
JP6950242B2 (ja) * 2017-03-31 2021-10-13 ブラザー工業株式会社 通信装置
SG11202006157VA (en) 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
CN112512572B (zh) 2018-04-20 2024-12-10 礼进生物医药科技（上海）有限公司 抗cd40抗体及其用途
CN112996818B (zh) 2018-09-28 2022-06-21 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
EP4048701A4 (en) * 2019-10-23 2024-05-29 Lyvgen Biopharma Holdings Limited Anti-cd40 binding molecules and bi-specific antibodies comprising such
JP2024532963A (ja) * 2021-04-08 2024-09-11 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ８特異的抗体コンストラクト及びその組成物
WO2026040746A1 (en) * 2024-08-19 2026-02-26 Hoffmann-La Roche Inc. Multispecific fusion proteins targeting angiogenic and inflammatory factors

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
IL88375A (en) * 1988-11-14 1995-07-31 Yeda Res & Dev Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method
CA1341588C (en) * 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP3614183B2 (ja) * 1993-05-31 2005-01-26 中外製薬株式会社 ヒトインターロイキン−６に対する再構成ヒト抗体
TW458985B (en) * 1993-05-31 2001-10-11 Chugai Pharmaceutical Co Ltd Reconstructed human antibody against human interleukin-6
FR2707882B1 (fr) * 1993-07-23 1997-08-01 Immunotech Sa Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
AU736282B2 (en) * 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
JP4463104B2 (ja) * 2002-08-30 2010-05-12 財団法人化学及血清療法研究所 ヒト抗ヒトインターロイキン−６抗体及び該抗体フラグメント
WO2004051268A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
CA2632628C (en) 2005-12-09 2016-01-19 Ucb Pharma S.A. Antibody molecules having specificity for human il-6

Also Published As

Publication number Publication date
AU2006323490A1 (en) 2007-06-14
KR20130100386A (ko) 2013-09-10
CN101356194A (zh) 2009-01-28
NO20083066L (no) 2008-09-08
DK1960430T3 (da) 2015-01-05
KR101413451B1 (ko) 2014-07-10
US9096668B2 (en) 2015-08-04
ES2525325T3 (es) 2014-12-22
EA200801427A1 (ru) 2008-12-30
PE20070998A1 (es) 2007-10-09
US20160039929A1 (en) 2016-02-11
US8075889B2 (en) 2011-12-13
US8486662B2 (en) 2013-07-16
WO2007066082A1 (en) 2007-06-14
IL191600A0 (en) 2008-12-29
JP5183484B2 (ja) 2013-04-17
US20070154481A1 (en) 2007-07-05
RS53708B1 (sr) 2015-04-30
AR057224A1 (es) 2007-11-21
ZA200804594B (en) 2010-08-25
US20140024077A1 (en) 2014-01-23
PL1960430T3 (pl) 2015-03-31
CA2632628A1 (en) 2007-06-14
IL191600A (en) 2015-11-30
CN101356194B (zh) 2013-06-12
US20170182159A1 (en) 2017-06-29
HRP20141214T1 (hr) 2015-02-13
TWI390035B (zh) 2013-03-21
KR20080077271A (ko) 2008-08-21
EP2336181A1 (en) 2011-06-22
KR101422523B1 (ko) 2014-07-24
BRPI0619595A8 (pt) 2019-01-15
HK1125113A1 (en) 2009-07-31
IL242434B (en) 2018-04-30
TW200728466A (en) 2007-08-01
SI1960430T1 (sl) 2015-01-30
EP1960430A1 (en) 2008-08-27
US20120183996A1 (en) 2012-07-19
CA2632628C (en) 2016-01-19
AU2006323490B2 (en) 2012-05-24
MY147217A (en) 2012-11-14
EP2314626A1 (en) 2011-04-27
PT1960430E (pt) 2015-01-05
UA96141C2 (ru) 2011-10-10
JP2009518023A (ja) 2009-05-07
BRPI0619595B1 (pt) 2020-09-15
BRPI0619595A2 (pt) 2011-10-04
NO344847B1 (no) 2020-05-25
EP1960430B1 (en) 2014-09-24
NZ569234A (en) 2011-07-29
BRPI0619595B8 (pt) 2022-12-13
US9631015B2 (en) 2017-04-25
EA018044B1 (ru) 2013-05-30

Similar Documents

Publication Publication Date Title
AR057224A1 (es) Moleculas de anticuerpo que tienen especificidad para la il- 6 humana
AR051484A1 (es) Moleculas de anticuerpo que tienen especificidad para la il - 17 humana
ECSP056014A (es) MOLÉCULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA
AR061538A1 (es) Moleculas de anticuerpo que se unen a la il-17 humana
UY32489A (es) Moléculas de anticuerpos que tienen especificidad de unión por il-13 humana
ECSP14000329A (es) Moléculas que son anticuerpos con especificidad por ox40 humano
CY1121431T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για τον ανθρωπινο οχ40
CO6781516A2 (es) Moléculas de anticuerpos que se unen a il-17a y il-17f
CY1121672T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
NI201100040A (es) Anticuerpos anti-il-13 modificados, composiciones, métodos y usos.
DOP2012000104A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
ECSP088778A (es) Formulacion de un anticuerpo monoclonal humano anti-igf-1r
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
CO6420355A2 (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
GT201200318A (es) Anticuerpos hacia gdf8 humano
UY31904A (es) Anticuerpos contra il-6 y sus usos
CO6331296A2 (es) Inmunoglobulinas de dominio variable dual y usos de las mismas
MX2017004196A (es) Anticuerpos contra ticagrelor y metodos de uso.
CL2022001684A1 (es) Anticuerpo con especificidad de unión para il-13 humana
CY1115868T1 (el) Μορια αντισωματων που εχουν ειδικο χαρακτηρα για το ανθρωπινο il-6